3rd Circuit Dupixent news shows skin cancer cases across New Jersey, Pennsylvania, and Delaware. While the full extent of lymphoma unmasking continues to emerge, MDL compensation is now being sought for eczema and asthma medication victims.
To learn more, please see our information on claiming a 3rd Circuit Dupixent settlement.
New Jersey Dupixent News
New Jersey Dupixent news reports indicate widespread development or unmasking of T-Cell lymphoma.
- NJ Dupixent News – Coming Soon / As Available
If you were diagnosed with skin cancer following eczema or asthma treatment, contact us about filing a New Jersey Dupixent lawsuit.
Pennsylvania Dupixent News
Pennsylvania Dupixent news reports indicate widespread development or unmasking of T-Cell lymphoma.
- PA Dupixent News – Coming Soon / As Available
If you were diagnosed with skin cancer following eczema or asthma treatment, contact us about filing a Pennsylvania Dupixent lawsuit.
Delaware Dupixent News
Delaware Dupixent news reports indicate widespread development or unmasking of T-Cell lymphoma.
- DE Dupixent News – Coming Soon / As Available
If you were diagnosed with skin cancer following eczema or asthma treatment, contact us about filing a Delaware Dupixent lawsuit.
3rd Circuit Dupixent News Supports MDL Settlement for Skin Cancer
3rd Circuit Dupixent news of T-cell lymphoma has raised concerns for eczema and asthma patients in New Jersey, Pennsylvania, and Delaware. As such, public support is growing for the court’s certification of a Dupixent Multi-District Litigation (MDL) to administer claims.
Lymphoma Attorneys Act on 3rd Circuit Dupixent News of Skin Cancer
Reporting skin cancer is an important first step to justice. If your family has been impacted by Dupixent, contact us about filing a 3rd Circuit settlement claim.
For background information on T-cell lymphoma, please see our Dupixent lawyers homepage.